In advanced tumours with distant diseases, the combination of chemotherapy with immunotherapy against the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) has achieved satisfactory outcomes in terms of increased survival [37]. The gene discussed is EGFR; the disease is neoplasm.